Fulgent Genetics, Inc. (FLGT) Tops Q3 EPS by 46c ; Offers Guidance

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q3 EPS of $0.31, $0.46 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $71.7 million versus the consensus estimate of $71.82 million.

GUIDANCE:

Fulgent Genetics, Inc. sees FY2024 revenue of ~$280 million, versus the consensus of $282.2 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• CFRA Starts SpaceX (SPCX) at Sell, 'Our primary concern is that SpaceX’s long-term strategy remains heavily dependent on Starship'
• UAE To Unlock Billions Of Dollars For Iran, Sources Say - Reuters
• Leerink highlights drug demand rebound after Memorial Day